Fremanezumab and Non-High-Dose Galcanezumab for Comorbid Cluster Headache in Patients with Migraine: Three Cases

A new treatment option for cluster headache (CH) prevention is needed. Monoclonal antibodies (mABs) against calcitonin gene-related peptide (CGRP) ligands are used as a preventative treatment for migraine. Considering the CGRP’s role in the CH attack’s ignition and upkeep, fremanezumab and galcanezu...

Full description

Bibliographic Details

Published in:	Neurology International
Main Authors:	Kenta Kashiwagi, Masahito Katsuki, Shin Kawamura, Senju Tachikawa, Atsuko Ono, Akihito Koh
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Subjects:	anti-calcitonin gene-related peptide monoclonal antibodies cluster headache migraine real-world galcanezumab fremanezumab
Online Access:	https://www.mdpi.com/2035-8377/15/1/20